Concepedia

Author

Jianjun Zou

Nanjing Medical UniversityORCID

Also Known As

J. Zou, JIANJUN ZOU, Jian-Jun Zou, Jian-jun Zou, JianJun Zou, Jianjun ZOU, Jianjun Zou, Jian‐Jun Zou, Jian‐jun Zou, Jing-Xia Zou

292

Publications

9.4K

Citations

44

H-Index

163

Concepts

All Affiliations

Nanjing Medical UniversityJiangsu Hengrui Medicine (China)China Pharmaceutical UniversityFudan University Shanghai Cancer CenterPeking University
JZ

About

Jianjun Zou is an author at Nanjing Medical University specializing in medicine, oncology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

29

54

5.1K

2

Health Sciences

10

10

1.8K

3

Engineering

8

8

262

4

Public Health

7

7

174

5

Social Sciences

1

1

24

Jianjun Zou

×

124

Publications

8.9K

Citations

43

H-Index

YearCitations

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Jin Lü, Yuxian Bai, Teng Mao,

JAMA

2021

746

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng,

The Lancet Oncology

2020

625

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen,

The Lancet Oncology

2020

568

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang,

The Lancet Respiratory Medicine

2020

488

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li,

The Lancet Oncology

2021

429

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma,

The Lancet Oncology

2021

372

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li,

Journal of Clinical Oncology

2019

335

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang, Yin Liu, Yi Xiao,

Cell Research

2020

298

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu,

Journal of Thoracic Oncology

2021

293

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu,

˜The œLancet. Gastroenterology & hepatology

2021

243

Page 1